HER2-Positive Early Stage Breast Cancer

Also known as: HER2-positive early-stage breast cancer / Early Stage HER2+ Breast Cancer / HER2-Positive Early Breast Cancer

DrugDrug NameDrug Description
DB05773Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
DrugDrug NamePhaseStatusCount
DB00958Carboplatin1 / 2Recruiting1
DB01248Docetaxel1 / 2Recruiting1
DB06366Pertuzumab1 / 2Recruiting1
DB00072Trastuzumab1 / 2Recruiting1
DB01222Budesonide2Completed1
DB00375Colestipol2Completed1
DB06205Hyaluronidase (human recombinant)2Completed1
DB01259Lapatinib2Completed1
DB00836Loperamide2Completed1
DB11828Neratinib2Completed1
DB01229Paclitaxel2Completed1
DB00019Pegfilgrastim2Completed1
DB06366Pertuzumab2Completed1
DB00072Trastuzumab2Completed2
DB14962Trastuzumab deruxtecan2Not Yet Recruiting1
DB00958Carboplatin3Completed1
DB00531Cyclophosphamide3Active Not Recruiting1
DB00531Cyclophosphamide3Recruiting1
DB01248Docetaxel3Active Not Recruiting1
DB01248Docetaxel3Completed1
DB00997Doxorubicin3Active Not Recruiting1
DB00997Doxorubicin3Recruiting1
DB06205Hyaluronidase (human recombinant)3Active Not Recruiting1
DB01229Paclitaxel3Recruiting1
DB06366Pertuzumab3Active Not Recruiting1
DB06366Pertuzumab3Recruiting1
DB00072Trastuzumab3Active Not Recruiting1
DB00072Trastuzumab3Completed1
DB00072Trastuzumab3Recruiting1
DB14962Trastuzumab deruxtecan3Recruiting1